329,000+ people newly diagnosed with Lyme disease in the US each year according to CDC1
Current “gold standard” diagnostic tests (ELISA) miss up to 60% of acute cases and <50% of patients recall any rash or remember a tick bite
Current Standard-of-Care antibiotic drugs are ineffective for ~20% of new Lyme patients who continue to exhibit symptoms even after treatment
20-30% treated for Lyme disease develop chronic pain, fatigue, and neurological symptoms
More than 2M people in the US could suffer from morbidities related to Post-Treatment Lyme Disease (PTLD) by the year 2020
With more than 329,000 estimated cases annually, Lyme disease is the most common tick-borne infection in North America (CDC 2019). The causative agent, Borrelia burgdorferi, is a spirochete that can chronically infect humans, causing rash, arthritis, carditis, myalgia, extreme fatigue and neurological dysfunction.
Despite generally effective treatment with antibiotics, a proportion of patients continue to experience symptoms after antibiotic treatment, a phenomenon that can be labeled as Post-Treatment Lyme Disease Syndrome (PTLDS). The efficacy and accepted regimen of antibiotic treatment for human borreliosis has been a very contentious issue. While evidence of ongoing infection has been difficult to diagnose, persistence in Lyme disease is a subject of substantial importance and animal studies have clearly demonstrated its existence. Hence, we need new medications to transform the treatment of PTLDS.
This is also a crucial scientific challenge, as we currently have no means to distinguish persistently-infected patients from those with lingering symptoms due to autoimmunity. Effective patient-centered treatment relies on the availability and use of drugs which can eradicate the infection(s).
Our goal at Flightpath is to significantly advance the understanding and practice of medicine for Lyme disease to aid millions of patients.